Warfarin versus aspirin in patients with reduced cardiac ejection fraction (WARCEF): rationale, objectives, and design.
暂无分享,去创建一个
B. Levin | John L.P. Thompson | P. Pullicino | R. Freudenberger | B. Barton | S. Graham | J. Thompson
[1] C. O'connor,et al. The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. , 2004, Journal of cardiac failure.
[2] Daniel Levy,et al. Long-term trends in the incidence of and survival with heart failure. , 2002, The New England journal of medicine.
[3] M. Redfield,et al. Heart failure--an epidemic of uncertain proportions. , 2002, The New England journal of medicine.
[4] R Brian Haynes,et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial , 1999, The Lancet.
[5] U. Goldbourt,et al. Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors: a cohort study of 11,575 patients with coronary artery disease. , 1999, Journal of the American College of Cardiology.
[6] B. Gersh,et al. Racial differences in the outcome of left ventricular dysfunction. , 1999, The New England journal of medicine.
[7] M. Ezekowitz. Antithrombotics for left-ventricular impairment? , 1998, The Lancet.
[8] W. Rand,et al. Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction. , 1998, Journal of the American College of Cardiology.
[9] W. Rand,et al. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. , 1998, Journal of the American College of Cardiology.
[10] T. Meade,et al. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk , 1998, The Lancet.
[11] W. O'Fallon,et al. Survival and recurrence after first cerebral infarction , 1998, Neurology.
[12] A. Algra,et al. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke , 1997, Journal of the Neurological Sciences.
[13] M. Rich,et al. CONGESTIVE HEART FAILURE IN OLDER ADULTS * : Epidemiology, Pathophysiology, and Etiology of Congestive Heart Failure in Older Adults , 1997, Journal of the American Geriatrics Society.
[14] B. Massie,et al. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. , 1997, American heart journal.
[15] J. Cleland. Anticoagulant and antiplatelet therapy in heart failure. , 1997, Current opinion in cardiology.
[16] M. Domanski,et al. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. , 1997, Journal of the American College of Cardiology.
[17] G. Lamas,et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. , 1997, The New England journal of medicine.
[18] M. Hennerici,et al. The Feasibility of a Collaborative Double-Blind Study Using an Anticoagulant , 1997 .
[19] M. Dennis. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee , 1996 .
[20] H. Diener,et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke 1 1 ESPS-2 Writing Committee , 1996, Journal of the Neurological Sciences.
[21] L. Tavazzi,et al. Systemic thromboembolism in chronic heart failure. A prospective study in 406 patients. , 1996, European heart journal.
[22] D. Singer,et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. , 1996, The New England journal of medicine.
[23] L. S. Mortensen,et al. Prognostic value of echocardiography in 190 patients with chronic congestive heart failure. A comparison with New York Heart Association functional classes and radionuclide ventriculography. , 1996, Cardiology.
[24] D. Clement. A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .
[25] P. Koudstaal. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. , 1995, The New England journal of medicine.
[26] J. Halperin,et al. Atrial fibrillation and stroke. Revisiting the dilemmas. , 1994, Stroke.
[27] R. Sacco,et al. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community , 1994, Neurology.
[28] Walker,et al. Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .
[29] T. LeJemtel,et al. Low incidence of stroke in ambulatory patients with heart failure: a prospective study. , 1993, American heart journal.
[30] J. Cohn,et al. Incidence of Thromboembolic Events in Congestive Heart Failure , 1993, Circulation.
[31] C Warlow,et al. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. , 1991, Journal of neurology, neurosurgery, and psychiatry.
[32] M. Laakso,et al. The European Stroke Prevention Study , 1991, Neurology.
[33] P Smith,et al. The effect of warfarin on mortality and reinfarction after myocardial infarction. , 1990, The New England journal of medicine.
[34] R. Falk. A plea for a clinical trial of anticoagulation in dilated cardiomyopathy. , 1990, The American journal of cardiology.
[35] V. Fuster,et al. Left ventricular thrombi and cerebral embolism. , 1989, The New England journal of medicine.
[36] J. Cairns,et al. Antithrombotic agents in coronary artery disease. , 1989, Chest.
[37] J Whitehead,et al. A FORTRAN program for the design and analysis of sequential clinical trials. , 1983, Computers and biomedical research, an international journal.
[38] P. Wolf,et al. Manifestations of coronary disease predisposing to stroke. The Framingham study. , 1983, JAMA.
[39] F. J. Moore,et al. A study of the beneficial effects of anticoagulant therapy in congestive heart failure. , 1952, Annals of internal medicine.
[40] G. Anderson,et al. The effect of dicumarol upon the mortality and incidence of thromboembolic complications in congestive heart failure. , 1950, American heart journal.
[41] W. P. Harvey,et al. Dicumarol prophylaxis of thromboembolic disease in congestive heart failure. , 1950, The New England journal of medicine.
[42] P. White,et al. Acute pulmonary congestion and cardiac asthma in patients with mitral stenosis , 1934 .